Loading
GemPharmatech Co., Ltd.: what insiders have been doing
GemPharmatech Co., Ltd. has a thin disclosure history in our data (latest filing: 4 August 2026). New filings will appear here as soon as they are published. Source: insider filings from SSE / SZSE (CSRC). Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€25,832
1 ops. · all time
Who traded when
BuySale粱娟1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 12,797 of 24,148 companies
49.9
score / 100
Value28
Quality72
FCF yld0.9%
Earn yld1.1%
EV/EBITDA51.3x
ROE8.2%
Gross mgn64%
Net mgn18%
Debt/EBITDA1.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CN¥32.63
Analyst consensus
1 analystsCN¥45.54Target CN¥45.54(+40%)CN¥45.54
Income statement
RevenueCN¥793.4M
Gross profitCN¥509M64% margin
EBITDACN¥259.2M33% margin
Net incomeCN¥142.6M20.8% margin
Valuation
PER (trailing)72.5x
P/Book5.9x
Beta0.87
Balance sheet & cash
Market capCN¥13.4B
Total debtCN¥291.3M
Free Cash FlowCN¥122M
Debt / Equity10%
Profitability & ownership
ROE8.2%
ROA4.2%
% insiders59.5%
% institutions15.0%
Last declaration on 4 August 2026
About GemPharmatech Co., Ltd.
药康生物 is a publicly traded company on the Shanghai Stock Exchange, specializing in the biopharmaceutical sector. It focuses on the development and commercialization of innovative drugs.
